
Opinion|Videos|August 7, 2024
Additional Data and Key Takeaways in CLL/SLL from EHA 2024
Author(s)Mazyar Shadman, MD, MPH
Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Are there any noteworthy key takeaways or additional data updates on CLL/SLL treatments discussed at EHA 2024 that you wish to share?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
4
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
5

































